PIN15 Use Of Anti-Infectives For Systemic Administration In Serbia In 2011  by Tomic, Z. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A81 
 
 
PIN10  
EFFECTS OF PILL BURDEN ON DISCONTINUATION OF THE INITIAL HAART 
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OBJECTIVES: Highly active antiretrovial therapy (HAART) is a mainstay of 
treatment for patients with Human Immunodeficiency Virus (HIV). Given that 
lower HAART pill burdens have been shown to be associated with an increased 
duration of initial therapy, there is a need to understand the effect of daily pill 
burden on the duration of the initial regimen. The objective of this study was to 
estimate the effects of daily pill burden on the time to discontinuation of the 
initial HAART regimen. METHODS: A retrospective cohort design was used 
where adult, female, HIV-positive patients initiating therapy at the study clinic 
were included. A Kaplan-Meier curve was generated and a Cox proportional 
hazards model was developed to assess the impact of patient, regimen, and 
demographic characteristics on the hazard of discontinuation of the initial 
regimen. RESULTS: A total of 498 charts were reviewed, yielding a cohort of 115 
adult female patients who initiated HAART at the study clinic. All study subjects 
were followed up from the initiation of HAART to treatment discontinuation. 
Patients treated with a 1 pill/day regimen had a significantly longer time to 
discontinuation than regimens of 2+ pills/day (mean duration of initial therapy 
1574.97 days vs. 977.48 days, respectively, p=0.003). Compared to 1 pill/day 
regimens, 2+ pills/day regimens were associated with a higher hazard of 
discontinuation (hazard ratio (HR) =3.44with 95% confidence interval (CI) = 1.25, 
9.48). Higher viral load and patients without insurance were also found to be 
significantly associated with higher hazards of discontinuation. CONCLUSIONS: 
The 1 pill/day regimen in the initial HAART treatment was associated with a 
lower hazard of discontinuation than any other regimen used.  
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OBJECTIVES: Monitoring transmitted drug resistance can inform national 
treatment recommendations, but U.S. data from patients initiating antiretroviral 
therapy (ART) are few. METHODS: Using data from HIV Outpatient Study (HOPS) 
participants from 10 U.S. HIV clinics diagnosed with HIV infection in 1999 or later 
and the International AIDS Society (IAS) December 2010 guidelines, we assessed 
the frequency of major ART resistance mutations in isolates from patients who 
underwent genotypic resistance testing (GT) before initiating ART. We used 
logistic regression to assess factors associated with having undergone GT and 
with harboring major IAS resistance. RESULTS: Among 1,484 eligible patients, 
711 (47.9%) had GT before first ART, increasing from 15.2% in 1999-2002 to 71.5% 
in 2009-2011 (p<0.001). During 1999-2011, patients who had GT were more likely 
to have been men who have sex with men, to have had CD4+ cell count >200 
cells/mm3, and to have had their first HOPS visit in 2003 or later (all p<0.05). Of 
695 (97.7%) patients with evaluable GT results, 114 (16.4%) had a major IAS-
defined mutation; mutations to nucleoside reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors and protease inhibitors were present, 
respectively, in 8.9%, 7.8% and 3.2% of patients. Four (0.6%) patients had triple-
class resistance and one patient had resistance to T-20, a drug in a novel fusion 
inhibitor class. We found no evidence of a temporal increase in the frequency of 
any major IAS mutation (13.2% in 1999-2002 to 17.5% in 2009-2011, p = 0.22) or in 
the frequency of mutations to any of the three main drug classes. 
CONCLUSIONS: During 1999-2011, GT use for ART-naive patients became more 
common without evidence of increases in frequency of transmitted HIV 
resistance in our large heterogeneous HIV cohort.  
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OBJECTIVES: To assess the effectiveness of the rotavirus monovalent vaccine in 
Colombia. METHODS: A hospital based case-control study was carried out. Cases 
were positive rotavirus diarrhea patients admitted to emergency departments in 
seven health care institutions across the country. Controls were non-rotavirus 
diarrhea patients admitted to emergency the department in those institutions. 
Vesikari scale was estimated to assess effectiveness of the vaccine against severe 
diarrhea. Multivariable analysis was made with logistic regression. A p-value 
<0.05 was considered statistically significant. RESULTS: A total of 60 cases and 
337 controls were used for analysis. Effectiveness of two-dose vaccination was 
46.8% (95% Confidence Interval [95%CI], -29.6 to 78.3). Effectiveness of two-dose 
vaccination applied at recommended age (less than 8 months of age) was 55.8% 
(95%CI, 7.3 to 78.9). Two-dose vaccination effectiveness in the multivariable 
analysis was 62.6% (95%CI, 0.30 to 85.9), and if applied at recommended age was 
71.9% (95%CI, 35.5 to 87.8). Results showed an effectiveness decline after 9 
months of vaccination. Effectiveness was 69% (95%CI, 26.7 to 86.9) during the 
nine months after vaccination, and 40.5% (95%CI, -31.3 to 73.1) after those nine 
months. CONCLUSIONS: Rotavirus vaccination with the monovalent vaccine was 
effective in Colombia, if applied to recommended age.  
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OBJECTIVES: To assess the clinical effectiveness of combined therapy with 
interferon (pegylated or non-pegylated) and ribavirin versus interferon alone for 
the treatment of chronic HCV in adult patients. METHODS: We used standard 
HTA methods as PICOs, comparative analysis, descriptive epidemiology to 
evaluate a clinical effectiveness of the anti HCV treatment in several respectable 
trials. Studies eligible for inclusion were systematic reviews of randomized 
controlled trials (RCTs), RCTs, HTA reports, economic evaluations, high quality 
primary studies (preferably RCTs). Preference was given to references published 
in the English or Russian languages and preferably published within the past 10 
years (2002 forward). RESULTS: All subgroups of included trials consisted of 
13,331 patients with chronic hepatitis C without HIV infection or liver 
transplantation with diagnosed on the presence of serum hepatitis C virus RNA 
plus elevated serum transaminase activity for more than 6 months or chronic 
hepatitis documented by liver biopsy. All of the included studies detected the 
clinical efficacy of combined therapy of IFN + RBV. According to trials, patients 
with non-1 genotype had higher virological response rates than patients with 
genotype 1. Genotype 1 patients had significantly higher SVR rates when treated 
for 48 weeks compared with 24 weeks. PEG and four IFN trials reported alanine 
aminotransferase (ALT) response rates after treatment. Sustained biochemical 
response was greater for IFN + RBV compared with IFN monotherapy or IFN with 
placebo, reaching significance in two trials and borderline significance in one 
trial. CONCLUSIONS: The clinical effectiveness of the combined therapy with 
ribavirin and interferon is convincing. However, using the ribavirin in 
combination with interferon (pegylated or non-pegylated) can not be final, owing 
to the many adverse effects. Assessment of the recovery of patients by the 
sustained virologic response should not be so pragmatic, because it is only a 
change of the "surrogate" criterias.  
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OBJECTIVES: The continuing spread of antimicrobial resistance, due to 
uncontrolled antibiotic use, is a major public health problem worldwide. The aim 
of this study is to make an inventory of the antimicrobials for systemic use in 
the home pharmacies of the urban and rural populations in South Ba ka District, 
Serbia. METHODS: This study was performed in 6 months period (February - July 
2010) on a sample of 208 households (108 in urban and 100 in rural communities) 
in South Ba ka District, Serbia. The families were chosen randomly and the data 
were collected by checking the inventory of antibiotics in the home pharmacies. 
RESULTS: The total number of drug packages present in 208 households was 
2221. Every other household had at least one package belonging to J01 class 
stored at home(51.0% in rural and 65.8% in urban households). A total number of 
89 packages belonging to J01 class were present in the surveyed rural families 
which constitutes 8.9% of total stored drugs. In urban families, the number of 
packages of antibiotics was 113 (9.3% of total drugs stored). The average number 
of antibacterial drug packages per household was 0.9 (range: 0-4) in rural and 1.0 
(range: 0-6) in urban families. The most frequent antibacterial agents both in 
rural and urban households was amoxicillin (20.1%), followed by cefalexin 
(14.8%) and amoxicillin+clavulanic acid (14.2%). CONCLUSIONS: According to this 
study, antibiotics are widely stocked among both rural and urban communities 
in South Ba ka District, Serbia, which requires further investigation of this 
practice.  
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OBJECTIVES: The aim of the study was to analyze of use of anti-infective drugs 
for systemic administration (ATC-group J) in Serbia in 2011 year. METHODS: Data 
about use of anti-infective drugs for systemic administration in Serbia in 2011 
was taken from the Agency for Drugs and Medical Devices of Serbia. RESULTS: 
Use of all drugs in Serbia in 2011 was 1,104.57 DDD/1000 inhabitants/day. ATC-
group J was on the seventh place according to amount of DDDs with 27.35 
DDD/1000 inh/day or 2.48% of total consumption. According to the funding 
spent, this group was on the second position with 77,800,748.63€. In this group, 
subgroup with highest consumption were antibacterial drugs for systemic use 
(subgroup J01), with 26.68 DDD/1000 inh/day or 97.55% of total use in group J. 
This subgroup takes first place in funding spent with 52,801,780.13€ or 67.87% of 
total expended finances in this group in 2011. Beta-lactam antibacterial drugs 
with 14.98 DDD/1000 inh/day or 56.15% were drugs with highest use in this 
subgroup, macrolides and lincosamides were at second place with 5.11 DDD/1000 
inh/day or 19.15%, while on the third place were quinolones with 2.66 DDD/1000 
inh/day or 9.97% of total drug utilization inside this subgroup. Funding spent on 
beta-lactam antibacterial drugs was 29,522,197.18€ or 55.91%, macrolides and 
lincosamides 10,811,308.09€ or 20.48%, and for quinolones 6,286,373.19€ or 
11.91% of total funding spent for subgroup J01 in 2011 year. CONCLUSIONS: In 
comparison to 2010 spending of group J in Serbia in 2011 year was increased for 
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7.72 DDD/1000 inh/day or 39.33%. However the amount of funding spent in this 
group of drugs was decreased for 12,850,895.28€ or 14.18%. This research was 
supported by Provincial Secretariat for Science and Technological Development, 
Autonomous Province of Vojvodina project No 114-451-2458/2011 and by 
Ministry of Science and Technological Development, Republic of Serbia project 
No 41012.  
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OBJECTIVES: Following solid organ transplantation (SOT) or hematopoietic stem 
cell transplantation (HSCT), patients are at risk of cytomegalovirus (CMV) 
disease. The impact of CMV disease on mortality, graft rejection, hospitalisation 
costs and on the probability of transplant rejection, failure or Graft versus Host 
Disease (GVHD) and other adverse events was estimated. METHODS: A 
retrospective cohort study of a database of hospitalisations in France (PMSI) from 
2007 to 2011 was conducted. Logistic regression was used to estimate the impact 
of CMV disease during initial hospitalisation on the probability of graft rejection 
and mortality over one year, adjusting for age, gender and comorbidities. The 
impact of CMV disease on costs and on length of stay (LOS) was estimated using 
generalised linear modeling, a correction for endogeneity was performed 
afterwards. RESULTS: Among 20,473 SOT and 18,809 HSCT recipients, CMV 
disease was reported in 9.72% and 6.65% of cases respectively. CMV disease was 
associated with a significant increase in mortality (SOT-patients: odds ratio=1.46, 
p=0.0552; HSCT-patients: OR=4.00, p<.0001). Patients with CMV disease at initial 
hospitalisation were more likely to experience graft rejection, failure or GVHD 
(SOT: OR =1.663, p= 0.0005; HSCT: OR=2.605, p <.0001). CMV was related to higher 
LOS and higher costs at initial stay for both subgroups (SOT: 8.7-days, €4,134, 
p<0.0001; HSCT: 8.75-days, €22,252, p<0.0001). The difference in total 
hospitalisation costs over 2 years between patients with and without CMV was 
€13,159 and €32,691 for SOT and HSCT recipients respectively. CMV disease was 
strongly associated with pneumonia (SOT: OR=3.37; HSCT: OR=3.37) and with 
enteritis (SOT: OR=3.63; HSCT: OR=3.90). CONCLUSIONS: CMV disease is 
associated with substantial increases in probability of graft rejection, mortality, 
length of stay, adverse events and hospitalisation costs in French transplant 
recipients. A limitation of this study is that it was not possible to adjust for the 
intensity of immunosuppressive therapy.  
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OBJECTIVES: Although effective chemotherapy is available, tuberculosis (TB) 
remains a major public health problem worldwide. The current study aimed to 
determine the prevalence of pulmonary TB and multi-drug resistant (MDR) TB in 
Baghdad, Iraq. METHODS: Databases of Thoracic and Respiratory Diseases 
Specialist Center were retrospectively reviewed to determine the prevalence of 
pulmonary TB in Baghdad. This center is the largest center for the diagnosis, 
treatment and recording of all new and previously treated TB cases in Baghdad 
and the other states of Iraq. All newly diagnosed TB patients who registered for 
TB treatment between January 1, 2011 and June 30, 2012 were included in the 
analysis. RESULTS: A total of 2968 TB cases were newly registered in Baghdad 
during the period under review. Of these, 1188 cases were smear positive 
pulmonary TB. The prevalence of smear positive and smear negative pulmonary 
TB in Baghdad were 40.02% (95% CI 34.46%-45.58%) and 16.81% (95% CI 12.56%-
21.06%) respectively. Additionally, 1810 of the newly diagnosed TB cases were 
male and 1158 were female. Baghdad accounted for 25.58% (95% CI 21.61%-
29.55%) of the estimated prevalence of smear positive pulmonary TB of the 
country. Furthermore, 103 laboratory-confirmed MDR-TB of new cases were 
reported in Baghdad during the same period. The estimated prevalence of MDR-
TB among newly diagnosed TB cases was 3.47% (95% CI 1.51%-5.43%). 
CONCLUSIONS: The results of the current study will have a significant 
implication for strengthening the TB control program in the capital Baghdad. In 
addition, actions to expand and plan the appropriate diagnostic and treatment 
services for patients with MDR-TB are warranted.  
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OBJECTIVES: To evaluate advanced liver disease outcomes of Medicare 
beneficiaries diagnosed with chronic hepatitis C virus (HCV). METHODS: This 
study was based on 2005-2010 CMS Fee-for-Service Medicare longitudinal claims 
data which includes 100% of the adjudicated medical claims for all inpatient and 
outpatient institutional providers and a 5% sample of adjudicated patient claims 
from the physician office setting. ICD-9 codes were used to identify patients with 
chronic HCV and advanced liver disease outcomes. Disease prevalence and 
trends over time were examined. RESULTS: In 2010, the prevalence rates of 
advanced liver disease such as non-decompensated liver disease (26.5% versus 
0.4%), decompensated cirrhosis (20.8% versus 1.6%), hepatocellular carcinoma 
(4.3% versus 0.1%), liver transplant (3.6% versus 0.06%), were higher (all 
statistically significant, p<0.0001) in the chronic HCV population than the non-
HCV population. Prevalence rates of complications remained stable across the 
six year period, with the exception of decompensated cirrhosis, the prevalence of 
which increased from 15.0% to 20.8% for chronic HCV patients and 0.6% to 1.6% 
in non-HCV patients. CONCLUSIONS: Evaluation of Medicare beneficiaries 
indicates that chronic HCV patients have a greater prevalence of advanced liver 
disease compared with non-HCV patients. The 6-year prevalence trend of 
decompensated cirrhosis has increased for both chronic HCV patients and non-
HCV patients.  
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OBJECTIVES: To characterize the demographics and comorbidities of US 
Medicare beneficiaries diagnosed with chronic hepatitis C virus (HCV) infection. 
METHODS: This study was based on 2005-2010 CMS Fee-for-Service Medicare 
longitudinal claims data which includes 100% of the adjudicated medical claims 
for all inpatient and outpatient institutional providers and a 5% sample of 
adjudicated patient claims from the physician office setting. ICD-9 codes were 
used to identify patients diagnosed with chronic HCV infection as well as the 
following comorbidities: anxiety, depression, alcohol abuse, HIV, and end stage 
renal disease (ESRD). RESULTS: A total of 368,871 chronic HCV patients were 
identified as having received Medicare benefits between 2005 and 2010. The 
average age of these chronic HCV patients in 2010 was 57.2 (SD=11.7) which is 14 
years younger than the non-HCV Medicare population (average = 71.0, SD=13.0). 
Only 28.4% of chronic HCV patients qualified for Medicare due to age alone (≥65 
years old) versus 82.0% of non-HCV patients. The majority of chronic HCV 
patients (63.4%) qualified for Medicare due to a disability that excludes ESRD, 
while only 16.9% of non-HCV patients met the same criteria. Chronic HCV 
patients exhibited a wide array of health problems. The prevalence rates of 
comorbidities such as anxiety (15.2% vs. 4.8%), depression (26.8% vs. 7.6%), 
alcohol abuse (40.9% vs. 2.1%), HIV (8.1% vs. 0.3%) and ESRD (8.5% versus 1.3%) 
were higher (all statistically significant, p<0.0001) in the chronic HCV population 
than the non-HCV population. CONCLUSIONS: Medicare beneficiaries are often 
generalized as over 65 years of age, but chronic HCV Medicare patients are 
typically younger and qualify for Medicare due to disability. The burden of 
patients with chronic HCV on Medicare is further exacerbated by the high 
prevalence of other costly comorbidities.  
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OBJECTIVES: To evaluate the prevalence of advanced liver disease outcomes 
within a large US database of commercially-insured individuals diagnosed with 
chronic hepatitis C virus (HCV) infection. METHODS: This study was based on 
2007-2011 IMS LifeLink claims data which includes adjudicated health claims 
data for 74 million patients and over 75 commercial health plans. ICD-9 codes 
were used to identify patients with chronic HCV and advanced liver disease 
outcomes. Trends in prevalence of these outcomes over time were also 
examined. RESULTS: In 2011, the prevalence rates of advanced liver disease such 
as non-decompensated liver disease (20.48% vs. 0.10%), decompensated cirrhosis 
(15.11% vs. 0.46%), hepatocellular carcinoma (3.43% vs. 0.03%), liver transplant 
(2.58% vs. 0.01%), were higher (all statistically significant, p<0.0001) in the 
chronic HCV population than the non-HCV population. Five-year prevalence 
trends of complications stayed stable, with the exception of decompensated 
cirrhosis and hepatocellular carcinoma. The prevalence of decompensated 
cirrhosis increased from 11.16% to 15.11% for chronic HCV patients and 0.31% to 
0.46% in non-HCV patients. The prevalence of hepatocellular carcinoma 
increased from 2.3% to 3.43% for chronic HCV patients and 0.02% to 0.03% in 
non-HCV patients. CONCLUSIONS: Evaluation of a large US database of 
commercially-insured individuals indicates that chronic HCV patients have a 
greater prevalence of advanced liver disease compared with non-HCV patients. 
The 5-year prevalence trend of decompensated cirrhosis has increased for both 
chronic HCV patients and non-HCV patients.  
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OBJECTIVES: To characterize the demographics and comorbidities of patients 
diagnosed with chronic hepatitis C virus (HCV) infection reporting claims to a 
large US database of commercially-insured individuals. METHODS: This study 
was based on 2007-2011 IMS LifeLink claims data which includes adjudicated 
health claims data for 74 million patients and over 75 commercial health plans. 
